WebDec 1, 2024 · Cisplatin is a widely used chemotherapy agent in the treatment of various forms of carcinomas and sarcomas. Its effectiveness in delaying negative outcome in cancer patients has been amply documented, and attributed primarily to its ability to crosslink DNA purine bases, thus interfering with DNA repair mechanisms in cancer cells. WebJan 18, 2024 · CX is the name of a combination of chemotherapy drugs; cisplatin and capecitabine. It is a treatment for a number of different types of cancer. Find out about …
Cisplatin in cancer treatment - ScienceDirect
WebObjectives: Cisplatin-induced ototoxicity is a common permanent consequence of curative chemoradiation for locally advanced head and neck squamous cell carcinoma (HNSCC). Predictors of ototoxicity in HNSCC were examined. Materials and methods: In this prospective, observational cohort study, 206 adult HNSCC patients underwent … WebCisplatin is a chemotherapy medication used to treat a number of cancers. These include testicular cancer, ovarian cancer, cervical cancer, bladder cancer, head and neck … flint and honey perth
Chemoradiotherapy with paclitaxel liposome plus cisplatin for …
WebApr 22, 2024 · Cancer cells repeatedly challenge researchers with their ability to develop resistance to treatments that were effective to begin with. Resistance to cisplatin, a platinum-based drug used as first-line chemotherapy treatment is a prominent example that has been extensively studied in the lab of Dr. Weei-Chin Lin, professor of medicine – … WebTreatment of lung cancer, the most common type of carcinoma, is difficult due to disease progression at the time of diagnosis, causing a high mortality rate. 1, 32 Cisplatin (DDP), also known as cis-diaminodichloplatin, is a powerful nonspecific drug blocking the cell cycle. 33, 34 DDP can enter cells through the passive transport. WebMar 22, 2024 · Here, we review the current role of cisplatin and carboplatin in the treatment of early stage and advanced triple-negative breast cancer (TNBC), and the use of biomarkers in predicting response to platinum therapy. Recent findings: The long-term benefit of the addition of carboplatin to standard chemotherapy regimens remains unproven. flint and kent buffalo ny